Teva Pharmaceutical Industries (TEVA) Receives a Buy from Raymond James
In a report released today, Elliot Wilbur from Raymond James maintained a Buy rating on Teva Pharmaceutical Industries (TEVA). The company’s shares closed last Monday at $9.09.
According to TipRanks.com, Wilbur ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.7% and a 40.5% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Sol-Gel Technologies, ANI Pharmaceuticals, and Perrigo Company.
The word on The Street in general, suggests a Hold analyst consensus rating for Teva Pharmaceutical Industries with a $12.33 average price target.
See today’s analyst top recommended stocks >>
Based on Teva Pharmaceutical Industries’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $4.36 billion and net profit of $69 million. In comparison, last year the company earned revenue of $4.34 billion and had a GAAP net loss of $689 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.